Retatrutide

LY3437943

An investigational triple receptor agonist being studied in phase 3 programmes for obesity and related metabolic conditions.

Licensed use — if any

Retatrutide is not an authorised medicine. Clinical-trial results and headlines do not make online powder or compounded versions approved products.

Research interest

Obesity, overweight and metabolic outcomes in controlled clinical studies with protocol-defined populations and safety monitoring.

Evidence lens

Known does not mean proven for everything.

The strongest claim on the page should never be stronger than the strongest source behind it.

What we can say

Multiple phase 3 studies are registered on ClinicalTrials.gov.
The programme evaluates efficacy and safety under formal trial controls.
FDA warns that retatrutide cannot be used in compounding under US federal law and should not be sold as an approved product.

What remains unknown

Final benefit–risk profile until trials and regulatory review are complete.
Long-term outcomes across broader populations.
Safety and identity of grey-market material sold under the same name.

Risk and caution

Class-related gastrointestinal, gallbladder, pancreatic and metabolic risks require formal evaluation rather than online assumptions.
Counterfeit or mislabelled material adds a separate manufacturing risk.
No dosing or sourcing guidance is provided.

Regulatory snapshot

Jurisdiction and context matter.

Investigational; not presented as an MHRA-authorised medicine. Check the current MHRA database for any future change.

Investigational and not FDA approved.

Tested sport

No sporting clearance is implied. Athletes should check the current WADA list and Global DRO as status and formulation matter.

Primary sources

Open the record.

Statuses change. Always check the current regulator, product label, trial record and anti-doping list.

This is not medical advice.

Do not start, stop or source a medicine based on this page. Speak to a qualified healthcare professional and use regulated supply routes. Call 999 in an emergency or NHS 111 for urgent advice.

Continue through the library →